

GÃ¼nter Niegisch

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/923486/publications.pdf>

Version: 2024-02-01

113
papers

2,647
citations

172386

29
h-index

233338

45
g-index

138
all docs

138
docs citations

138
times ranked

3916
citing authors

#	ARTICLE	IF	CITATIONS
1	Nomograms including the UBC [®] Rapid test to detect primary bladder cancer based on a multicentre dataset. <i>BJU International</i> , 2022, 130, 754-763.	1.3	6
2	Cognitive function in patients undergoing cystectomy for bladder cancer – results from a prospective observational study. <i>Therapeutic Advances in Urology</i> , 2022, 14, 175628722210876.	0.9	2
3	Proteomic and transcriptomic profiles of human urothelial cancer cells with histone deacetylase 5 overexpression. <i>Scientific Data</i> , 2022, 9, .	2.4	4
4	Influence of a Deep Learning Noise Reduction on the CT Values, Image Noise and Characterization of Kidney and Ureter Stones. <i>Diagnostics</i> , 2022, 12, 1627.	1.3	6
5	Downregulation of Cell Cycle and Checkpoint Genes by Class I HDAC Inhibitors Limits Synergism with G2/M Checkpoint Inhibitor MK-1775 in Bladder Cancer Cells. <i>Genes</i> , 2021, 12, 260.	1.0	13
6	Prodigiosin Sensitizes Sensitive and Resistant Urothelial Carcinoma Cells to Cisplatin Treatment. <i>Molecules</i> , 2021, 26, 1294.	1.7	13
7	Epigenetic Treatment of Urothelial Carcinoma Cells Sensitizes to Cisplatin Chemotherapy and PARP Inhibitor Treatment. <i>Cancers</i> , 2021, 13, 1376.	1.7	4
8	CTLA4 promoter hypomethylation is a negative prognostic biomarker at initial diagnosis but predicts response and favorable outcome to anti-PD-1 based immunotherapy in clear cell renal cell carcinoma. , 2021, 9, e002949.		22
9	Late toxicities and recurrences in patients with clinical stage I non-seminomatous germ cell tumours after 1 cycle of adjuvant bleomycin, etoposide and cisplatin versus primary retroperitoneal lymph node dissection – A 13-year follow-up analysis of a phase III trial cohort. <i>European Journal of Cancer</i> , 2021, 155, 64-72.	1.3	10
10	Epigenetic Priming of Bladder Cancer Cells With Decitabine Increases Cytotoxicity of Human EGFR and CD44v6 CAR Engineered T-Cells. <i>Frontiers in Immunology</i> , 2021, 12, 782448.	2.2	15
11	Efficacy of Surgery in the Primary Tumor Site for Metastatic Urothelial Cancer: Analysis of an International, Multicenter, Multidisciplinary Database. <i>European Urology Oncology</i> , 2020, 3, 94-101.	2.6	41
12	Complication rate after cystectomy following pelvic radiotherapy: an international, multicenter, retrospective series of 682 cases. <i>World Journal of Urology</i> , 2020, 38, 1959-1968.	1.2	22
13	Ramucirumab plus docetaxel versus placebo plus docetaxel in patients with locally advanced or metastatic urothelial carcinoma after platinum-based therapy (RANGE): overall survival and updated results of a randomised, double-blind, phase 3 trial. <i>Lancet Oncology</i> , The, 2020, 21, 105-120.	5.1	61
14	Predicting immune checkpoint inhibitor response in urothelial carcinoma: another step in personalised medicine?. <i>British Journal of Cancer</i> , 2020, 122, 453-454.	2.9	3
15	Many Different LINE-1 Retroelements Are Activated in Bladder Cancer. <i>International Journal of Molecular Sciences</i> , 2020, 21, 9433.	1.8	9
16	Therapeutic implications of PD-L1 expression in bladder cancer with squamous differentiation. <i>BMC Cancer</i> , 2020, 20, 230.	1.1	24
17	Evaluation of HER2 expression in urothelial carcinoma cells as a biomarker for circulating tumor cells. <i>Cytometry Part B - Clinical Cytometry</i> , 2020, 98, 355-367.	0.7	10
18	Combination of Decitabine and Entinostat Synergistically Inhibits Urothelial Bladder Cancer Cells via Activation of FoxO1. <i>Cancers</i> , 2020, 12, 337.	1.7	23

#	ARTICLE	IF	CITATIONS
19	Basic Hallmarks of Urothelial Cancer Unleashed in Primary Uroepithelium by Interference with the Epigenetic Master Regulator ODC1. <i>Scientific Reports</i> , 2020, 10, 3808.	1.6	12
20	Unfavorable Cancer-specific Survival After Neoadjuvant Chemotherapy and Radical Cystectomy in Patients With Bladder Cancer and Squamous Cell Variant: A Multi-institutional Study. <i>Clinical Genitourinary Cancer</i> , 2020, 18, e543-e556.	0.9	22
21	Knockdown of LTX/KDM6A Enriches Precursor Cell Populations in Urothelial Cell Cultures and Cell Lines. <i>Cancers</i> , 2020, 12, 1023.	1.7	5
22	Should we spare neoadjuvant chemotherapy in low-risk muscle-invasive bladder cancer patients scheduled for radical cystectomy?. <i>Translational Andrology and Urology</i> , 2019, 8, S283-S286.	0.6	0
23	Metastatic Bladder Cancer Disease and Its Treatment. , 2019, , 403-411.		0
24	Incremental Utility of Adjuvant Chemotherapy in Muscle-invasive Bladder Cancer: Quantifying the Relapse Risk Associated with Therapeutic Effect. <i>European Urology</i> , 2019, 76, 425-429.	0.9	15
25	Distinctive mutational spectrum and karyotype disruption in long-term cisplatin-treated urothelial carcinoma cell lines. <i>Scientific Reports</i> , 2019, 9, 14476.	1.6	8
26	HDAC5 Expression in Urothelial Carcinoma Cell Lines Inhibits Long-Term Proliferation but Can Promote Epithelial-to-Mesenchymal Transition. <i>International Journal of Molecular Sciences</i> , 2019, 20, 2135.	1.8	14
27	Modeling 1-year Relapse-free Survival After Neoadjuvant Chemotherapy and Radical Cystectomy in Patients with Clinical T2a€“4NOM0 Urothelial Bladder Carcinoma: Endpoints for Phase 2 Trials. <i>European Urology Oncology</i> , 2019, 2, 248-256.	2.6	11
28	The Impact of Cisplatin- or Non-Cisplatin-Containing Chemotherapy on Long-Term and Conditional Survival of Patients with Advanced Urinary Tract Cancer. <i>Oncologist</i> , 2019, 24, 1348-1355.	1.9	10
29	Development of a Prediction Tool for Exclusive Locoregional Recurrence After Radical Cystectomy in Patients With Muscle-Invasive Bladder Cancer. <i>Clinical Genitourinary Cancer</i> , 2019, 17, 7-14.e3.	0.9	9
30	Oncological outcome of patients treated with spot-specific salvage lymphnode dissection (sLND) for positron-emission tomography (PET)-positive prostate cancer (PCa) relapse. <i>World Journal of Urology</i> , 2019, 37, 2081-2090.	1.2	5
31	Lack of Effectiveness of Postchemotherapy Lymphadenectomy in Bladder Cancer Patients with Clinical Evidence of Metastatic Pelvic or Retroperitoneal Lymph Nodes Only: A Propensity Score-based Analysis. <i>European Urology Focus</i> , 2019, 5, 242-249.	1.6	11
32	5-factor prognostic model for survival of patients with metastatic urothelial carcinoma receiving three different post-platinum PD-L1 inhibitors.. <i>Journal of Clinical Oncology</i> , 2019, 37, 4552-4552.	0.8	3
33	Validated five-factor prognostic model for survival of patients (pts) with metastatic urothelial carcinoma (mUC) receiving different post-platinum PD-L1 inhibitors.. <i>Journal of Clinical Oncology</i> , 2019, 37, 476-476.	0.8	0
34	Squamous-cell carcinoma variant histology (SCC-VH) in muscle-invasive bladder cancer (MIBC): A comprehensive clinical, genomic, and therapeutic assessment from multiple datasets.. <i>Journal of Clinical Oncology</i> , 2019, 37, 4535-4535.	0.8	0
35	Impact of timing of adjuvant chemotherapy following radical cystectomy for bladder cancer on patient survival.. <i>Journal of Clinical Oncology</i> , 2019, 37, e16017-e16017.	0.8	0
36	Impact of contemporary patterns of chemotherapy utilization on survival in patients with advanced cancer of the urinary tract: a Retrospective International Study of Invasive/Advanced Cancer of the Urothelium (RISC). <i>Annals of Oncology</i> , 2018, 29, 361-369.	0.6	57

#	ARTICLE	IF	CITATIONS
37	Atezolizumab in Platinum-treated Locally Advanced or Metastatic Urothelial Carcinoma: Outcomes by Prior Number of Regimens. <i>European Urology</i> , 2018, 73, 462-468.	0.9	36
38	Targeting urothelial carcinoma cells by combining cisplatin with a specific inhibitor of the autophagy-inducing class III PtdIns3K complex. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2018, 36, 160.e1-160.e13.	0.8	33
39	Robot-assisted Versus Open Radical Cystectomy in Patients Receiving Perioperative Chemotherapy for Muscle-invasive Bladder Cancer: The Oncologistâ€™s Perspective from a Multicentre Study. <i>European Urology Focus</i> , 2018, 4, 937-945.	1.6	7
40	Bone Metastases as the Only Metastatic Site in Patients With Urothelial Carcinoma: Focus on a Special Patient Population. <i>Clinical Genitourinary Cancer</i> , 2018, 16, e483-e490.	0.9	12
41	Radical cystectomy or bladder preservation with radiochemotherapy in elderly patients with muscle-invasive bladder cancer: Retrospective International Study of Cancers of the Urothelial Tract (RISC) Investigators. <i>Acta OncolÃ³gica</i> , 2018, 57, 491-497.	0.8	22
42	Venous Thromboembolism Risk in Patients With Locoregional Urothelial Tract Tumors. <i>Clinical Genitourinary Cancer</i> , 2018, 16, e161-e167.	0.9	3
43	Epigenetic Treatment Options in Urothelial Carcinoma. <i>Methods in Molecular Biology</i> , 2018, 1655, 289-317.	0.4	1
44	Does robotic radical cystectomy impede oncological outcome in bladder cancer patients?. <i>Translational Andrology and Urology</i> , 2018, 7, S744-S746.	0.6	2
45	Neoadjuvant vs. Adjuvant Chemotherapy in Muscle Invasive Bladder Cancer (MIBC): Analysis From the RISC Database. <i>Frontiers in Oncology</i> , 2018, 8, 463.	1.3	27
46	Impact of the Number of Cycles of Platinum Based First Line Chemotherapy for Advanced Urothelial Carcinoma. <i>Journal of Urology</i> , 2018, 200, 1207-1214.	0.2	26
47	A Real-World Data Study to Evaluate Treatment Patterns, Clinical Characteristics and Survival Outcomes for First- and Second-Line Treatment in Locally Advanced and Metastatic Urothelial Cancer Patients in Germany. <i>Journal of Cancer</i> , 2018, 9, 1337-1348.	1.2	45
48	Effects of novel HDAC inhibitors on urothelial carcinoma cells. <i>Clinical Epigenetics</i> , 2018, 10, 100.	1.8	51
49	Comparison of 2-Year Oncological Outcome and Early Recurrence Patterns in Patients with Urothelial Bladder Carcinoma Treated with Open or Robot-Assisted Radical Cystectomy with an Extracorporeal Urinary Diversion. <i>Urologia Internationalis</i> , 2018, 101, 224-231.	0.6	8
50	Multifaceted Mechanisms of Cisplatin Resistance in Long-Term Treated Urothelial Carcinoma Cell Lines. <i>International Journal of Molecular Sciences</i> , 2018, 19, 590.	1.8	29
51	Combined inhibition of BET proteins and class I HDACs synergistically induces apoptosis in urothelial carcinoma cell lines. <i>Clinical Epigenetics</i> , 2018, 10, 1.	1.8	93
52	New 6-factor prognostic model for patients (pts) with advanced urothelial carcinoma (UC) receiving post-platinum atezolizumab.. <i>Journal of Clinical Oncology</i> , 2018, 36, 413-413.	0.8	10
53	Impact of number of cycles of platinum-based first-line chemotherapy for advanced urothelial carcinoma.. <i>Journal of Clinical Oncology</i> , 2018, 36, 426-426.	0.8	3
54	Tumor immunotherapyâ€™the potential of epigenetic drugs to overcome resistance. <i>Translational Cancer Research</i> , 2018, 7, 1151-1160.	0.4	11

#	ARTICLE	IF	CITATIONS
55	Metastatic Bladder Cancer Disease and Its Treatment. , 2018, , 1-9.		0
56	Nomogram-based risk prediction of local and distant relapse after radical cystectomy, and role of perioperative chemotherapy, in patients with muscle-invasive bladder cancer (MIBC): A multicenter study.. Journal of Clinical Oncology, 2018, 36, 448-448.	0.8	0
57	MP52-08 ONCOLOGICAL OUTCOMES, SURGICAL SAFETY AND COMPLICATIONS OF PATIENTS TREATED WITH SPOT SPECIFIC SALVAGE LYMPHNODE DISSECTION (SLND) FOR POSITRON-EMISSION TOMOGRAPHY (PET) POSITIVE PROSTATE CANCER (PCA) RELAPSE. Journal of Urology, 2018, 199, .	0.2	0
58	Relapse-free survival (RFS) of clinical T2-4N0 urothelial bladder carcinoma (UBC) after radical cystectomy (RC), with or without perioperative chemotherapy (POC): Endpoints for clinical trial design.. Journal of Clinical Oncology, 2018, 36, 4535-4535.	0.8	0
59	Venous thromboembolism in metastatic urothelial carcinoma or variant histologies: incidence, associative factors, and effect on survival. Cancer Medicine, 2017, 6, 186-194.	1.3	12
60	Applying the chicken embryo chorioallantoic membrane assay to study treatment approaches in urothelial carcinoma. Urologic Oncology: Seminars and Original Investigations, 2017, 35, 544.e11-544.e23.	0.8	17
61	Nomogram-based Prediction of Overall Survival in Patients with Metastatic Urothelial Carcinoma Receiving First-line Platinum-based Chemotherapy: Retrospective International Study of Invasive/Advanced Cancer of the Urothelium (RISC). European Urology, 2017, 71, 281-289.	0.9	56
62	Ramucirumab plus docetaxel versus placebo plus docetaxel in patients with locally advanced or metastatic urothelial carcinoma after platinum-based therapy (RANGE): a randomised, double-blind, phase 3 trial. Lancet, The, 2017, 390, 2266-2277.	6.3	153
63	PD24-03 ONCOLOGICAL OUTCOMES OF PATIENTS TREATED WITH SALVAGE LYMPHNODE DISSECTION (SLND) FOR POSITRON-EMISSION TOMOGRAPHY (PET) POSITIVE PROSTATE CANCER (PCA) RELAPSE. Journal of Urology, 2017, 197, .	0.2	0
64	Targeting mTOR in urothelial cancerâ€”Beating a dead horse or ready for prime time?. Urologic Oncology: Seminars and Original Investigations, 2017, 35, 600-601.	0.8	0
65	Checkpoint kinase inhibitor AZD7762 strongly sensitises urothelial carcinoma cells to gemcitabine. Journal of Experimental and Clinical Cancer Research, 2017, 36, 1.	3.5	76
66	Various Mechanisms Involve the Nuclear Factor (Erythroid-Derived 2)-Like (NRF2) to Achieve Cytoprotection in Long-Term Cisplatin-Treated Urothelial Carcinoma Cell Lines. International Journal of Molecular Sciences, 2017, 18, 1680.	1.8	13
67	Real-world survival outcomes in patients with advanced urothelial cancer in Germany. Annals of Oncology, 2017, 28, v396-v397.	0.6	0
68	Diagnostic and prognostic value of long noncoding RNAs as biomarkers in urothelial carcinoma. PLoS ONE, 2017, 12, e0176287.	1.1	39
69	Atezolizumab (atezo) in platinum-treated locally advanced or metastatic urothelial carcinoma (mUC): Outcomes by prior therapy.. Journal of Clinical Oncology, 2017, 35, 323-323.	0.8	4
70	HDACs and HDAC Inhibitors in Urothelial Carcinoma â€” Perspectives for an Antineoplastic Treatment. Current Medicinal Chemistry, 2017, 24, 4151-4165.	1.2	21
71	Are bladder cancer patients set at risk by minimally invasive approaches to radical cystectomy?. Translational Cancer Research, 2017, 6, S221-S225.	0.4	0
72	The New Immortalized Uroepithelial Cell Line HBLAK Contains Defined Genetic Aberrations Typical of Early Stage Urothelial Tumors. Bladder Cancer, 2016, 2, 449-463.	0.2	34

#	ARTICLE	IF	CITATIONS
73	Quality of life in patients with cisplatin-resistant urothelial cancer: Typical ailments and effect of paclitaxel-based salvage therapy. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2016, 34, 256.e15-256.e21.	0.8	10
74	Impact of Prior Platinum-Based Therapy on Patients Receiving Salvage Systemic Treatment for Advanced Urothelial Carcinoma. <i>Clinical Genitourinary Cancer</i> , 2016, 14, 494-498.	0.9	1
75	Cisplatin- Versus Nonâ€“Cisplatin-based First-Line Chemotherapy for Advanced Urothelial Carcinoma Previously Treated With Perioperative Cisplatin. <i>Clinical Genitourinary Cancer</i> , 2016, 14, 331-340.	0.9	12
76	Evaluation of the Therapeutic Potential of the Novel Isozyme Specific HDAC Inhibitor 4SC-202 in Urothelial Carcinoma Cell Lines. <i>Targeted Oncology</i> , 2016, 11, 783-798.	1.7	52
77	Patterns of Bladder Preservation Therapyâ€™Utilization for Muscle-Invasive Bladder Cancer. <i>Bladder Cancer</i> , 2016, 2, 405-413.	0.2	12
78	Inhibition of Class I Histone Deacetylases 1 and 2 Promotes Urothelial Carcinoma Cell Death by Various Mechanisms. <i>Molecular Cancer Therapeutics</i> , 2016, 15, 299-312.	1.9	48
79	Single-agent Taxane Versus Taxane-containing Combination Chemotherapy as Salvage Therapy for Advanced Urothelial Carcinoma. <i>European Urology</i> , 2016, 69, 634-641.	0.9	53
80	Phenotype plasticity rather than repopulation from CD90/CK14+ cancer stem cells leads to cisplatin resistance of urothelial carcinoma cell lines. <i>Journal of Experimental and Clinical Cancer Research</i> , 2015, 34, 144.	3.5	27
81	Do Orthotopic Ileal Diversions Induce Immunological Changes in Retained Urethral Tissue?. <i>Bladder Cancer</i> , 2015, 1, 97-103.	0.2	4
82	Truncated Isoforms of lncRNA ANRIL Are Overexpressed in Bladder Cancer, But Do Not Contribute to Repression of INK4 Tumor Suppressors. <i>Non-coding RNA</i> , 2015, 1, 266-284.	1.3	20
83	The long noncoding RNA HOTAIR has tissue and cell type-dependent effects on HOX gene expression and phenotype of urothelial cancer cells. <i>Molecular Cancer</i> , 2015, 14, 108.	7.9	72
84	Second-Line Treatment of Advanced Urothelial Cancer with Paclitaxel and Everolimus in a German Phase II Trial (AUO Trial AB 35/09). <i>Oncology</i> , 2015, 89, 70-78.	0.9	26
85	Complete Response as an Intermediate End Point in Patients Receiving Salvage Systemic Therapy forâ€™Urothelial Carcinoma. <i>Clinical Genitourinary Cancer</i> , 2015, 13, 185-192.	0.9	2
86	Cisplatin-Based First-Line Therapy for Advanced Urothelial Carcinoma After Previous Perioperative Cisplatin-Based Therapy. <i>Clinical Genitourinary Cancer</i> , 2015, 13, 178-184.	0.9	15
87	Impact of the Number of Prior Lines of Therapy and Prior Perioperative Chemotherapy in Patients Receiving Salvage Therapy for Advanced Urothelial Carcinoma: Implications for Trial Design. <i>Clinical Genitourinary Cancer</i> , 2015, 13, 71-79.	0.9	10
88	Epigenetics of Urothelial Carcinoma. <i>Methods in Molecular Biology</i> , 2015, 1238, 183-215.	0.4	16
89	Canonical Notch signalling is inactive in urothelial carcinoma. <i>BMC Cancer</i> , 2014, 14, 628.	1.1	29
90	Limited efficacy of specific HDAC6 inhibition in urothelial cancer cells. <i>Cancer Biology and Therapy</i> , 2014, 15, 742-757.	1.5	36

#	ARTICLE	IF	CITATIONS
91	Multiple Mechanisms Mediate Resistance to Sorafenib in Urothelial Cancer. <i>International Journal of Molecular Sciences</i> , 2014, 15, 20500-20517.	1.8	30
92	A nomogram including baseline prognostic factors to estimate the activity of secondâ€line therapy for advanced urothelial carcinoma. <i>BJU International</i> , 2014, 113, E137-43.	1.3	31
93	Concomitant downregulation of the imprinted genes DLK1 and MEG3 at 14q32.2 by epigenetic mechanisms in urothelial carcinoma. <i>Clinical Epigenetics</i> , 2014, 6, 29.	1.8	33
94	Perioperative complications and oncological safety of robot-assisted (RARC) vs. open radical cystectomy (ORC). <i>Urologic Oncology: Seminars and Original Investigations</i> , 2014, 32, 966-974.	0.8	33
95	Histone deacetylase 8 is deregulated in urothelial cancer but not a target for efficient treatment. <i>Journal of Experimental and Clinical Cancer Research</i> , 2014, 33, 59.	3.5	27
96	Pathological T0 Following Radical Cystectomy with or without Neoadjuvant Chemotherapy: A Useful Surrogate. <i>Journal of Urology</i> , 2014, 191, 898-906.	0.2	51
97	Six-Month Progression-Free Survival as the Primary Endpoint to Evaluate the Activity of New Agents as Second-line Therapy for Advanced Urothelial Carcinoma. <i>Clinical Genitourinary Cancer</i> , 2014, 12, 130-137.	0.9	27
98	MTDH/AEG-1 contributes to central features of the neoplastic phenotype in bladder cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2014, 32, 670-677.	0.8	24
99	Patient Eligibility and Trial Design for the Salvage Therapy of Advanced Urothelial Carcinoma. <i>Clinical Genitourinary Cancer</i> , 2014, 12, 395-398.	0.9	12
100	Impact of Response to Prior Chemotherapy in Patients With Advanced Urothelial Carcinoma Receiving Second-Line Therapy: Implications for Trial Design. <i>Clinical Genitourinary Cancer</i> , 2013, 11, 495-500.	0.9	20
101	Neoadjuvant Chemotherapy in Patients with Muscle-invasive Bladder Cancer: Which Patients Benefit?. <i>European Urology</i> , 2013, 64, 355-357.	0.9	29
102	Changes in histone deacetylase (HDAC) expression patterns and activity of HDAC inhibitors in urothelial cancers. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2013, 31, 1770-1779.	0.8	68
103	Time from Prior Chemotherapy Enhances Prognostic Risk Grouping in the Second-line Setting of Advanced Urothelial Carcinoma: A Retrospective Analysis of Pooled, Prospective Phase 2 Trials. <i>European Urology</i> , 2013, 63, 717-723.	0.9	104
104	HERV-K and LINE-1 DNA Methylation and Reexpression in Urothelial Carcinoma. <i>Frontiers in Oncology</i> , 2013, 3, 255.	1.3	49
105	Rs11892031[A] on chromosome 2q37 in an intronic region of the UGT1A locus is associated with urinary bladder cancer risk. <i>Archives of Toxicology</i> , 2012, 86, 1369-1378.	1.9	32
106	Urinary bladder cancer risk in relation to a single nucleotide polymorphism (rs2854744) in the insulin-like growth factor-binding protein-3 (IGFBP3) gene. <i>Archives of Toxicology</i> , 2012, 86, 195-203.	1.9	14
107	Which patients benefit the most from neoadjuvant chemotherapy in advanced bladder cancer?. <i>Current Opinion in Urology</i> , 2011, 21, 434-439.	0.9	7
108	Prognostic Factors in Second-Line Treatment of Urothelial Cancers With Gemcitabine and Paclitaxel (German Association of Urological Oncology Trial AB20/99). <i>European Urology</i> , 2011, 60, 1087-1096.	0.9	25

#	ARTICLE	IF	CITATIONS
109	Randomized phase III trial of 2nd line gemcitabine and paclitaxel chemotherapy in patients with advanced bladder cancer: short-term versus prolonged treatment [German Association of Urological Oncology (AUO) trial AB 20/99]. <i>Annals of Oncology</i> , 2011, 22, 288-294.	0.6	129
110	Genotyping NAT2 with only two SNPs (rs1041983 and rs1801280) outperforms the tagging SNP rs1495741 and is equivalent to the conventional 7-SNP NAT2 genotype. <i>Pharmacogenetics and Genomics</i> , 2011, 21, 673-678.	0.7	50
111	Rs710521 [A] on chromosome 3q28 close to TP63 is associated with increased urinary bladder cancer risk. <i>Archives of Toxicology</i> , 2010, 84, 967-978.	1.9	37
112	Activation of classical protein kinase C reduces the expression of human cationic amino acid transporter 3 (hCAT-3) in the plasma membrane. <i>Biochemical Journal</i> , 2006, 395, 117-123.	1.7	13
113	Distinct mechanisms contribute to acquired cisplatin resistance of urothelial carcinoma cells. <i>Oncotarget</i> , 0, 7, 41320-41335.	0.8	16